文献速递类风湿关节炎

阿达木单抗联合或不联合甲氨蝶呤治疗多关节型幼年特发性关节炎的6年长期结局

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
PubMed 文献 · RMD Open · 2020-01-01

这项III期随机撤药双盲安慰剂对照试验纳入171例4-17岁多关节型幼年特发性关节炎患儿,按基线甲氨蝶呤使用分层,在16周开放导入期、32周随机双盲期及360周长期扩展期中评估阿达木单抗的安全性与疗效。6年暴露期间阿达木单抗耐受性良好,未见心力衰竭相关不良事件、脱髓鞘疾病、狼疮样综合征、恶性肿瘤、结核或死亡,但长期扩展完成率仅36%。

要点

  • 6年暴露期间报告11例患者的12例严重感染,未报告结核、恶性肿瘤、狼疮样综合征或死亡。
  • 第104周时66%至96%的患者达到JIA ACR 30/50/70/90应答及JADAS27低疾病活动度。
  • 37%的患者在研究期间达到临床缓解,早期JIA ACR 50及以上应答与JADAS27低疾病活动度或非活动性疾病是最佳预测因素。

核心结论

  • 多关节型JIA患者接受阿达木单抗治疗至6年暴露时耐受性良好,可获得显著临床应答甚至临床缓解,但长期保留率相对较低。

研究设计与样本

  • III期随机撤药双盲安慰剂对照试验,纳入171例4-17岁多关节型JIA患儿,按基线甲氨蝶呤使用分层。
  • 试验包括16周开放标签导入期、32周随机双盲期和360周长期扩展期,共评估6年治疗。

主要发现

  • 171例入组患者中62例(36%)完成长期扩展;592.8患者年暴露期间报告11例患者的12例严重感染。
  • 未报告心力衰竭相关不良事件、脱髓鞘疾病、狼疮样综合征、恶性肿瘤、结核或死亡。
  • 第104周时66%至96%的患者达到JIA ACR 30/50/70/90应答及JADAS27低疾病活动度(≤3.8)。
  • 63例(37%)患者在研究期间达到临床缓解,即JADAS27非活动性疾病(≤1)持续至少连续6个月。
  • 早期达到JIA ACR 50及以上应答及JADAS27低疾病活动度或非活动性疾病是临床缓解的最佳预测因素。

关键数值与推荐

  • 研究定义JADAS27低疾病活动度为≤3.8,非活动性疾病为≤1。
  • 临床缓解定义为JADAS27非活动性疾病持续至少连续6个月。
  • 平均JADAS27从基线22.5(n=170)降至第312周2.5(n=30,观察分析)。

临床怎么用

  • 对多关节型JIA患儿可考虑阿达木单抗治疗并长期监测感染等不良事件。
  • 早期JIA ACR 50及以上应答及JADAS27低疾病活动度或非活动性疾病可提示长期临床缓解可能。
  • 需注意长期治疗保留率相对较低,应结合个体情况评估持续治疗策略。

局限性

  • 长期扩展完成率仅36%,完成长期随访的患者样本量较小。
  • 第312周JADAS27均值基于观察分析且样本量仅30例,解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Long-term safety and efficacy of adalimumab among patients with juvenile idiopathic arthritis (JIA) was evaluated through 6 years of treatment. METHODS: Children aged 4-17 years with polyarticular JIA were enrolled in a phase III, randomised-withdrawal, double-blind, placebo-controlled trial consisting of a 16-week open-label lead-in period, 32-week randomised double-blind period and 360-week long-term extension. Patients were stratified by baseline methotrexate use. Adverse events (AEs) were monitored, and efficacy assessments included JIA American College of Rheumatology (JIA ACR) 30%, 50%, 70% or 90% responses and the proportions of patients achieving 27-joint Juvenile Arthritis Disease Activity Score (JADAS27) low disease activity (LDA, ≤3.8) and inactive disease (ID, ≤1). RESULTS: Of 171 patients enrolled, 62 (36%) completed the long-term extension. Twelve serious infections in 11 patients were reported through 592.8 patient-years of exposure. No cases of congestive heart failure-related AEs, demyelinating disease, lupus-like syndrome, malignancies, tuberculosis or deaths were reported. JIA ACR 30/50/70/90 responses and JADAS27 LDA were achieved in 66% to 96% of patients at week 104, and 63 (37%) patients achieved clinical remission (JADAS27 ID sustained for ≥6 continuous months) during the study. Attainment of JIA ACR 50 or higher and JADAS27 LDA or ID in the initial weeks were the best predictors of clinical remission. Mean JADAS27 decreased from baseline, 22.5 (n=170), to 2.5 (n=30) at week 312 (observed analysis). CONCLUSIONS: Through 6 years of exposure, adalimumab was well tolerated with significant clinical response (up to clinical remission) and a relatively low retention rate.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Lovell DJ, Brunner HI, Reiff AO, et al. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open. 2020. PMID: 32665432. doi:10.1136/rmdopen-2020-001208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。